Big Money Are Buying Intercept Pharmaceuticals Inc (NASDAQ:ICPT), Sentiment at 1.27

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Corporate Logo

Intercept Pharmaceuticals Inc’s Sentiment

In Q2 2018 Intercept Pharmaceuticals Inc (NASDAQ:ICPT) big money sentiment increased to 1.27, SEC.gov filings reveal. That’s up 0.12, from 2018Q1’s 1.15. 70 active investment managers increased or opened new holdings, while 55 cut down and sold their positions in Intercept Pharmaceuticals Inc so the sentiment has increased. Funds own 19.65 million shares, up from 18.85 million shares in 2018Q1. Funds holding Intercept Pharmaceuticals Inc in top 10 increased from 1 to 2 for an increase of 1. In total 15 funds closed positions, 40 reduced and 45 increased. Also 25 funds bought new Intercept Pharmaceuticals Inc stakes.

Biggest Intercept Pharmaceuticals Inc Shareholders

As of Q2 2018 Sarissa Capital Management Lp has 10.69% invested in Intercept Pharmaceuticals Inc. Intercept Pharmaceuticals Inc’s shareholder Elk Creek Partners Llc owns 386,397 shares as of Q2 2018. In addition, Bb Biotech Ag reported 545,719 shares in Intercept Pharmaceuticals Inc equivalent to 1.32% of its fund’s portfolio. The Connecticut-based fund Altrinsic Global Advisors Llc have invested about 1.27% of the investment manager’s stock portfolio in Intercept Pharmaceuticals Inc. The New York-based fund Opus Point Partners Management Llc holds 3,998 shares or 0.73% of their fund’s portfolio.

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases.The company has $3.23 billion market cap. The Company’s lead product candidate is obeticholic acid , a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR).Last it reported negative earnings. The firm is developing OCA to treat various non-viral progressive liver diseases, such as nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia.

Ticker’s shares touched $108.81 during the last trading session after 4.38% change.Currently Intercept Pharmaceuticals, Inc. is uptrending after 19.09% change in last November 10, 2017. ICPT has also 315,653 shares volume. The stock outperformed the S&P 500 by 3.47%.

Parametric Portfolio Limited Liability Company accumulated 0% or 58,257 shs. Citadel Advisors Limited Company owns 613,221 shs or 0.03% of their US capital. Zurcher Kantonalbank (Zurich Cantonalbank) stated it has 1,054 shs. First Trust Advsrs Ltd Partnership owns 840,584 shs. Bokf Na reported 0.02% of its capital in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). 122,561 are owned by Credit Suisse Ag. Fisher Asset Management Ltd Liability Company reported 44,587 shs. Morgan Stanley accumulated 81,996 shs. Winslow Evans & Crocker holds 0% of its capital in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) for 16 shs. Hall Laurie J Trustee accumulated 60 shs. Moreover, Bnp Paribas Arbitrage has 0% invested in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) for 11,411 shs. Dsc Limited Partnership has invested 0.14% in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). Price Capital Mgmt holds 8,446 shs or 0.35% of its capital. Susquehanna Group Llp reported 26,151 shs stake. The New York-based Sg Americas Secs Ltd has invested 0% in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT).

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Ratings Coverage

In total 7 analysts cover Intercept Pharmaceuticals (NASDAQ:ICPT). “Buy” rating has 5, “Sell” are 0, while 2 are “Hold”. 71% are bullish. 8 are the (NASDAQ:ICPT)’s analyst reports since June 28, 2018 according to StockzIntelligence Inc. On Monday, August 6 the stock of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) earned “Outperform” rating by Wedbush. On Friday, August 3 the company was downgraded by Laidlaw. On Monday, August 6 Goldman Sachs upgraded Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) to “Buy” rating. On Monday, October 1 the stock has “Overweight” rating by Cantor Fitzgerald. The company rating was downgraded by Raymond James on Tuesday, October 2. The company rating was downgraded by RBC Capital Markets on Wednesday, August 15.

For more Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) news posted briefly go to: Nasdaq.com, Nasdaq.com, Seekingalpha.com, Seekingalpha.com or Fool.com. The titles are as follows: “Intercept Announces New OCA Data to be Presented at The Liver Meeting® 2018” posted on November 05, 2018, “Report: Developing Opportunities within Vitamin Shoppe, Intercept Pharmaceuticals, Viasat, Team, Valvoline, and …” on October 24, 2018, “Intercept Pharmaceuticals And PSC: Primed To Profit” with a publish date: October 24, 2018, “Intercept Pharmaceuticals (ICPT) Q3 2018 Results – Earnings Call Transcript” and the last “Forget Gilead Sciences: Intercept Pharmaceuticals, Inc. Is a Better Growth Stock” with publication date: October 16, 2018.

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.